Phase 2 N=16 Vaccination of Triple Negative Breast Cancer Patients
Triple Negative Breast Cancer · Breast Neoplasms
Primary: Safety and Tolerability Adverse Events — 8; 81 Total events
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=71 Ambispective Clinical Evaluation of Sophono™
Conductive Hearing Loss · Single-Sided Deafness · Mixed Hearing Loss
Primary: Safety Outcome Measure: Proportion of Adverse Events (AEs) Related to Sophono Implant — 0.038 Proportion of Adverse Events
N/A N=22 Compassion Meditation for Older Adults
Anxiety and Mood Disorders
Primary: Enrollment Rate — 25; 0 Participants
Phase 3 N=62 HEXT (Hypo EXTended): Effect of PTH on Skeleton in Hypoparathyroidism
Hypoparathyroidism
Primary: Change in Dose of Calcium Supplementation — 37 percent change in dose
Phase 3 N=105 Thromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous Lines
Upper Extremity Deep Vein Thrombosis · Central Venous Catheter Thrombosis · Cancer
Primary: Primary Feasibility Outcome - Number of Participants Recruited Per Month — 7.5; 2.0 Average enrolment rate/month/site
N/A N=55 An Intervention to Promote Smoking Cessation Among Adults With Food Insecurity
Smoking Cessation · Food Insecurity
Primary: Number of 24-hour Quit Attempts — 2.6; 1.8 number of 24-hour quit attempts
N/A N=5 The Impact of a Home-based Pulmonary Telerehabilitation Program in Acute Exacerbations of COPD
Pulmonary Disease, Chronic Obstructive
Primary: Quadriceps Muscle Strength Testing Change
Phase 1 N=396 A Bioequivalence Study of Mirikizumab (LY3074828) in Healthy Participants
Healthy
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab — 13.0; 12.9 micrograms per milliliter (μg/mL)
N/A N=657 Measuring Cardiovascular Performance and Blood Flow Using Common But Never Compared Methods.
D012039 · D001775
Primary: Feasibility of Performing Echo, BNP, and VP on Human Subjects. — 657; 236 Participants
Early Phase 1 N=9 Vitamin A Palmitate Supplementation in Patients With Reticular Pseudodrusen (RPD) and Delayed Dark Adaptation
Reticular Pseudodrusen (RPD) · Age-Related Macular Degeneration
Primary: Change in Dark Adaptation Rod Intercept Time (RIT) From Baseline in the Study Eye at the Treatment Completion Visit (Month 2 for Cohort 1 and Month 1 for Cohort 2)…
N/A N=1,261 Personalized Assessment of Client Experiences
Mental Disorder in Adolescence
Primary: Change in The Ohio Scales Problem Severity Scale Youth Report — -4.4; 4.92 score on a scale — p=.25
Early Phase 1 N=60 Individual Differences in Drug Response
Differential Female Response to Δ9-tetrahydrocannabinol (THC)
Primary: Change From Baseline in Profile of Mood States (POMS) — 2.58; 4.28; 8.25; 0.7 units on a scale
Phase 3 N=100 A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)
Acute Bacterial Skin and Skin Structure Infections
Primary: Number of Participants Who Experienced an Adverse Event (AE) — 7; 2; 7; 2 Participants
Early Phase 1 N=46 Companion: Sensor-based Two-way Communication for Physical Activity in Older Adults
Exercise · Physical Activity
Primary: Physical Activity Hours Per Day Measured Using a Body-worn Accelerometer at Baseline — 1.3; 1.6 h/day — p=0.037
Phase 4 N=530 Trial of Andexanet Alfa in ICrH Patients Receiving an Oral FXa Inhibitor
Acute Intracranial Hemorrhage
Primary: Number of Participants Who Achieved Effective Hemostasis — 150; 121 Participants — p=0.0032